Cell-Free DNA Amplification Using Protelomerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional cell-based DNA amplification processes are costly, inefficient, and prone to errors, particularly in producing high-purity closed linear DNA molecules required for therapeutic applications, due to the complexity of bacterial systems and the risk of contamination and recombination events.
Innovation Solution
An in vitro, cell-free process using DNA polymerase and protelomerase to amplify and convert DNA templates into closed linear covalently closed DNA, eliminating the need for host cells and reducing purification costs by directly producing closed linear DNA molecules with enhanced stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional cell-based processes are used for DNA amplification, then DNA can be produced in large quantities, but the production cost is high and purification is complex due to the need to eliminate endotoxins and bacterial components
Solution Approach 1:
The invention extracts the DNA amplification function from the bacterial host system and performs it in a cell-free environment. By removing the bacterial cell component entirely and using only purified enzymes (DNA polymerase, protelomerase) and substrates in vitro, the process eliminates the need to purify DNA from bacterial contaminants and endotoxins, directly solving the purification complexity problem while maintaining high-yield production
Solution Approach 2:
The invention introduces purified enzymes (DNA polymerase and protelomerase) as intermediaries to mediate the DNA amplification and processing reactions. These enzyme intermediaries perform the functions previously carried out by bacterial cellular machinery, enabling DNA production without requiring living bacterial cells, thereby eliminating endotoxin contamination while maintaining production efficiency
2Quantity of substance
If bacterial systems are used for DNA amplification, then large-scale production is achieved, but fidelity is compromised due to recombination events and bacterial alterations of the cloned gene
Solution Approach 1:
The invention extracts the amplification function from the complex bacterial cellular environment and transfers it to a simplified cell-free system. By removing the bacterial host and its problematic cellular processes (recombination, gene alteration), the system maintains high fidelity while achieving large-scale production through controlled enzymatic reactions with high-performance DNA polymerases that have proofreading capability
Solution Approach 2:
The invention changes the fundamental parameters of the amplification system from a living bacterial organism to a controlled in vitro enzymatic system. By using purified high-fidelity DNA polymerases with proofreading activity and optimizing reaction conditions (temperature, buffer composition, dNTP concentrations), the system achieves both high yield and high fidelity, eliminating the reliability problems associated with bacterial systems
3Productivity
If plasmid-based amplification is used, then DNA can be produced efficiently, but the product contains extraneous nucleotide sequences that are not required for medicinal function
Solution Approach 1:
The invention extracts only the essential elements needed for DNA amplification (template DNA, primers, enzymes, dNTPs) and eliminates the plasmid vector and its extraneous sequences (antibiotic resistance genes, origin of replication, promoter regions). The cell-free system amplifies only the desired DNA sequence without requiring plasmid-based delivery, directly producing high-purity DNA suitable for medicinal applications
Solution Approach 2:
The invention performs preliminary design of the DNA template and primers to ensure that only the required medicinal DNA sequence is amplified. By carefully designing the template DNA and primers to match exactly the desired product sequence, and by using protelomerase to process the amplified DNA into the final closed-linear form, the system produces high-purity DNA without extraneous sequences, eliminating the need for subsequent purification steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process significantly increases productivity, reduces costs, and ensures high-purity closed linear DNA production, improving the manufacturing of DNA medicines by eliminating extraneous sequences and enhancing stability and safety for therapeutic applications.
Implementation Method 1
contacting a DNA template comprising at least one protelomerase target sequence with at least one DNA polymerase in the presence of one or more primers under conditions promoting amplification of said template
Implementation Method 2
contacting amplified DNA produced in (a) with at least one protelomerase under conditions promoting production of closed linear DNA
Data Source
AI summary
An in vitro process for the production of closed linear deoxyribonucleic acid (DNA) comprises (a) contacting a DNA template comprising at least one protelomerase target sequence with at least one DNA polymerase in the presence of one or more primers under conditions promoting amplification of the template; and (b) contacting amplified DNA produced in (a) with at least one protelomerase under conditions promoting production of closed linear DNA. A kit provides components necessary in the process.